Cefotaxime Resistance in Treatment of Spontaneous Bacterial Peritonitis
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
Spontaneous bacterial peritonitis (SBP) is a serious complication in cirrhotic patients, and
the changes in the microbiological characteristics reported in the last years are impacting
the choice of antibiotic used in the treatment. Cefotaxime has been the most extensively
studied antibiotic for this infection. It is considered to be one of the first choice
antibiotics because of low toxicity and excellent efficacy. Treatment of SBP by intravenous
cefotaxime should be administered for a minimum 5 days. Antibiotic-resistant microorganisms
have been increasingly reported especially to cefotaxime and its effect on the clinical
outcome in treating SBP.